Addex and indivior select clinical candidates from gabab positive allosteric modulator research collaboration

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, august 27, 2024 - addex therapeutics (six/nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and indivior plc (nasdaq/lse: indv) today announced the selection of clinical candidates from their gabab positive allosteric modulator (pam) research collaboration.
ADXN Ratings Summary
ADXN Quant Ranking